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Abstract 
Background: Type 2 diabetes mellitus (T2DM) is associated with a hypercoagulable state and increased neutrophil 
extracellular traps formation (NETosis). We investigated predictors of NETosis and cell death markers in circulating 
blood and their association with a prothrombotic state in T2DM.
Methods: In a cross-sectional study involving 113 T2DM patients aged 63.7 ± 8.2 years, we investigated citrullinated 
histone H3 (H3Cit), cell-free deoxyribonucleic acid (cfDNA), myeloperoxidase, neutrophil elastase, and inflamma-
tion markers, along with thrombin generation (TG), plasma clot lysis time (CLT), clot permeability  (Ks) and fibrinolysis 
inhibitors.
Results: On multivariate logistic regression analysis adjusted for age and gender, predictors of high H3Cit (≥ 7.36 ng/
mL, upper quartile) were: glycated hemoglobin (HbA1c) ≥ 7.0% and interleukin-6. Interleukin-6 was also found to 
be a predictor of high cfDNA (≥ 2.84 µg/mL, upper quartile) along with glucose. Citrullinated histone H3 and cfDNA 
correlated positively with CLT and inversely with  Ks, while TG associated solely with cfDNA. These associations were 
not seen with myeloperoxidase and neutrophil elastase. Patients with previous myocardial infarction (n = 21, 18.6%) 
had higher H3Cit (+108%, p < 0.001) and cfDNA (+45%, p = 0.022). On multivariable analysis adjusted for potential 
confounders, H3Cit and cfDNA, along with plasminogen activator inhibitor-1 and concomitant cardiovascular disease, 
were predictors of CLT. Citrullinated histone H3 alone was a predictor of  Ks and only cfDNA was a predictor of peak 
thrombin generated.
Conclusions: In T2DM, NETosis detectable in circulating blood is associated with inflammatory state and a prothrom-
botic state, especially hypofibrinolysis.
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Background
A prothrombotic fibrin clot phenotype involves faster 
formation of dense meshwork composed of thinner 
and highly branched fibres which are relatively resist-
ant to plasmin-induced lysis [1]. A number of diseases 
have been demonstrated to be associated with such 
unfavourable clot properties, including type 2 diabetes 
mellitus (T2DM) [2]. Decreased clot permeability [3] 
and impaired efficiency of fibrinolysis [4] in T2DM have 
been attributed to multiple alterations, including elevated 
plasminogen activator inhibitor 1 (PAI-1) [5] and throm-
bin activatable fibrinolysis inhibitor (TAFI) [6], increased 
glycation of fibrinogen [7] and plasminogen [8], and 
enhanced thrombin generation (TG) [9] in association 
with low-grade systemic inflammation [4].
There is growing evidence showing that inflammation 
and increased blood coagulation are in part related to 
each other via formation of neutrophil extracellular traps, 
NETosis [10]. NETs are structures composed of nuclear 
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components such as histones and deoxyribonucleic acid 
(DNA), and granule constituents, such as myeloper-
oxidase and neutrophil elastase (NE), which disarm and 
kill bacteria extracellularly [11]. Addition of histones to 
the plasma of healthy volunteers has been demonstrated 
to stimulate TG [12]. In patients with coronary artery 
disease (CAD), double-stranded DNA, nucleosomes, 
citrullinated histone H4, and myeloperoxidase–DNA 
complexes, have been shown to positively associate with 
formation of thrombin-antithrombin complexes [13]. In a 
purified system, the addition of histone-DNA complexes 
to fibrinogen has been shown to result in thicker, more 
stable and rigid fibrin fibres and prolonged clot lysis [14]. 
It has been suggested that this effect may be DNA con-
centration-dependent [15], although in  vitro NETs are 
considered to display largely antifibrinolytic properties 
[14].
Little is known about NETosis in T2DM. It has been 
demonstrated that in  vitro, a high glucose concentra-
tion may either impair [16] or increase [17] NETs forma-
tion. Moreover, enhanced inflammation, as evidenced by 
elevated interleukin-6 (IL-6), promoted NETosis in vitro 
[16]. Increased plasma nucleosomes, extracellular DNA, 
and NE levels in association with glycated haemoglo-
bin (HbA1c) have been reported in patients with T2DM 
compared with non-diabetic individuals [17]. To the best 
of our knowledge, it is unclear whether NETosis, detecta-
ble in circulating blood, could contribute to a thrombotic 
tendency, including the prothrombotic clot phenotype, 
observed in T2DM patients.
Cardiovascular disease (CVD) and diabetic kidney 
disease have been identified as factors associated with 
increased extracellular DNA in a small group of 38 
patients with T2DM [17], while metformin has been 
found to reduce histones, DNA, and NE detectable in 
the blood of patients with pre-diabetes [18] or newly-
diagnosed T2DM [19]. The impact of anti-diabetic agents 
in patients with long-lasting T2DM on NETosis markers 
has not been studied.
We aimed to investigate factors which determine 
NETosis in T2DM and the contribution of circulating 
markers of NETosis and cell death to a prothrombotic 
state in patients with T2DM.
Methods
Study design
In this cross-sectional study, we enrolled Caucasian 
patients aged ≥ 18  years who fulfilled the World Health 
Organization criteria for T2DM [20]. Patients were 
recruited in Cracow, Poland, between October 2016 
and July 2017. The exclusion criteria were as follows: 
signs of acute infection, arterial or venous thrombo-
embolic events within the previous 6  months, current 
anticoagulant therapy, known cancer, recent trauma or 
surgery, autoimmune diseases, and pregnancy. All sub-
jects provided written, informed consent. The Bioethics 
Committee at the Jagiellonian University Medical College 
approved the study.
Demographic and clinical data, including the time 
since T2DM diagnosis, were collected at enrolment. 
Arterial hypertension was diagnosed if a patient met 
one of the following criteria: (1) a history of hyperten-
sion; (2) antihypertensive treatment prior to admission; 
(3) consistent systolic or diastolic pressure ≥ 140 mmHg 
or ≥ 90  mmHg, respectively. CVD was defined as docu-
mented stable CAD, peripheral artery disease (PAD), 
stroke or transient ischemic attack due to the vascular 
disease confirmed by imaging [21]. CAD was diagnosed 
in all patients who had previous myocardial infarction 
(MI), underwent percutaneous coronary intervention, 
or in all patients with signs and symptoms and positive 
results of either non-invasive testing or invasive coronary 
angiography [22]. Previous MI, ischaemic stroke, or pre-
vious revascularisation was established based on medical 
records. PAD was diagnosed based on symptoms with 
an ankle-brachial index < 0.9, and prior revascularisation 
[23]. For the detection of albuminuria, the threshold of 
albumin-to-creatinine ratio (30  mg/g) was used [24] in 
subjects without urinary tract infection symptoms.
Laboratory investigations
Fasting blood samples were obtained from antecubital 
vein between 6 and 8 A.M. White blood cells, haemo-
globin, platelet count, fasting glucose, creatinine, ala-
nine aminotransferase, activated partial thromboplastin 
time (aPTT), prothrombin time and lipid profile were 
assayed by routine laboratory techniques. Glomerular 
filtration rate (GFR) was calculated using the Chronic 
Kidney Disease Epidemiology Collaboration equation. 
High-sensitivity C-reactive protein (hs-CRP) was meas-
ured by latex-enhanced turbidimetric immunoassay 
using a Cobas 6000 analyser (Roche Diagnostics GmbH, 
Mannheim, Germany; Hitachi High-Technologies Cor-
poration, Tokyo, Japan). HbA1c was measured by high-
performance liquid chromatography using the Variant II 
Turbo analyser (Hercules, CA, USA).
NETs components
Commercially-available ELISA kits were used to quan-
tify citrullinated histone H3 (H3Cit, Cayman Chemical, 
Ann Arbor, MI, USA), neutrophil elastase (NE, Abcam, 
Cambridge, MA, USA), myeloperoxidase, IL-6, and inter-
leukin 8 (IL-8, R&D Systems, Minneapolis, MN, USA). 
Concentration of cfDNA was measured using the assay 
kit (Invitrogen, Life Technologies, CA, USA) according to 
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manufacturer’s instructions. High H3Cit and high cfDNA 
were defined as H3Cit and cfDNA, respectively, in the 
upper quartile.
Coagulation and fibrinolysis parameters
To obtain citrated plasma, blood samples were mixed 
with 3.2% sodium citrate (9:1), centrifuged for 20  min 
and stored at − 80  °C. Fibrinogen was determined with 
the von Clauss method. Plasminogen and α2-antiplasmin 
were measured by chromogenic assays (Siemens, 
Munich, Germany). Commercially available immunoen-
zymatic assays were used to measure plasma PAI-1 anti-
gen (Hyphen, Neuville-sur-Oise, France), TAFI (Hyphen, 
Neuville-sur-Oise, France), thrombomodulin (Diagnos-
tica Stago, Parsippany, NJ, USA), P-selectin and platelet 
factor 4 (R&D Systems, Minneapolis, MN, USA).
Calibrated automated thrombogram (CAT)
Assessment of the TG profile was performed as pre-
viously described [25]. Citrated plasma samples were 
thawed at 37  °C for 3  min and 5  mg/mL corn trypsin 
inhibitor was immediately added to achieve a 0.1  mg/
mL final concentration. Eighty μL of each plasma sam-
ple was added to a 96-well plate followed by addition of 
relipidated tissue factor [26] at a final concentration of 
5  pM. The fluorogenic substrate used was benzyloxy-
carbonyl-Gly-Gly-Arg-7-amido-4methyl-coumarin·HCl 
(Z-GGR-AMC) (Bachem, Torrance, CA, USA). Twenty 
millilitre of a 2.5 mM Z-GGR-AMC/90 mM  CaCl2 solu-
tion in HEPES-buffered saline was added to plasma 
samples to achieve final concentrations of 417  μM and 
15 mM, respectively. A 3 min incubation period at 37 °C 
followed to allow recalcification of the plasma. Twenty 
millilitre of a 120 μM phospholipid vesicle solution (25% 
dioleoyl-sn-glycero-3-phospho-l serine and 75% 1,2-dio-
leoyl-sn-glycero-3-phosphocholine) (Avanti Polar Lipids, 
Inc, Alabaster, Al) in HEPES-buffered saline was then 
added to plasma samples to achieve a final concentra-
tion of 20 μM, thus initiating TG. Fluorescence readings 
began immediately and hydrolysis of the AMC (7-amino-
4-methylcoumarin) substrate (at 370  nm excitation 
and 460  nm emission wavelengths) was followed over a 
3600 s period. Changes in fluorescence were converted to 
thrombin concentration using a calibration curve built by 
sequential dilutions of human thrombin (Haematologic 
Technologies, Inc., Essex Junction, VT). Human throm-
bin was produced in-house [27]. The plate reader used 
was the BioTek Synergy 4 and analysis was performed 
using the Gen5 plate reader software (BioTek, Winooski, 
VT, USA).
Clot permeability and clot lysis time (CLT)
Fibrin clot permeability was determined as previously 
described [28, 29]. Briefly, 20  mmol/L calcium chloride 
and 1 U/mL human thrombin were added to 120  µL of 
citrated plasma. After incubation in a wet chamber for 
120 min, tubes containing the clots were connected to a 
reservoir of a Tris buffer pH 7.5, and after washing, flow 
rates of buffer through the fibrin clots were measured by 
timing the permeation of consecutive drops through each 
tube within 60 min and recording the weight of each drop 
for exact volume. A permeation coefficient  (Ks), which 
indicates the size of fibrin clot pores, was calculated from 
the following equation:  Ks = Q×L × η/t × A×Δp, where 
Q is the flow rate in time (t); L, the length of a fibrin gel; 
η, the viscosity of liquid (in poise); A, the cross-sectional 
area (in square centimetres), and Δp, a differential pres-
sure (in dynes per square centimetre).
CLT was measured as described [30]. Briefly, cit-
rated plasma was mixed with 15  mM calcium chloride, 
10,000×-diluted human tissue factor (Innovin, Siemens), 
with a final concentration of 0.6 pM, 12 µmol/L phospho-
lipid vesicles (highly purified phosphatidylcholine, phos-
phatidylserine, and sphingomyelin from Rossix, Mölndal, 
Sweden), and 60 ng/mL recombinant tissue plasminogen 
activator (Boehringer Ingelheim, Ingelheim, Germany). 
The mixture was transferred to a microtiter plate and 
its turbidity was measured at 405 nm at 37 °C. Clot lysis 
time was defined as the time from the midpoint of the 
clear-to-maximum-turbid transition, which represents 
clot formation, to the midpoint of the maximum-turbid 
to-clear transition (representing the lysis of the clot).
Statistical analysis
Categorical variables were presented as numbers (per-
centages) and compared by Fisher’s exact test for 
2 × 2 contingency tables (if 20% of cells have expected 
count less than 5), Pearson’s chi-squared test was used 
otherwise. Continuous variables were expressed as 
mean ± standard deviation or median (interquartile 
range). Normality was assessed by the Shapiro–Wilk test. 
Equality of variances will be assessed using the Levene’s 
test. NETs markers were dichotomized into 2 groups by 
using an upper quartile split. Differences between groups 
were compared using the Student’s or the Welch’s t test 
depending on the equality of variances for normally dis-
tributed variables. The Mann–Whitney U test was used 
for comparison of two non–normally distributed contin-
uous variables, while more groups were compared using 
the Kruskal–Wallis test. Post-hoc comparisons were 
made using the Steel–Dwass method. The association 
between two continuous variables was assessed by Pear-
son’s or Spearman’s rank correlation. The odds ratio of 
high H3Cit and cfDNA were determined by multivariate 
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forward regression and presented with 95% confidence 
interval (95% CI). To study determinants of TG, CLT and 
 Ks, univariate and multivariate regression analyses were 
performed. Multivariate models were fitted using back-
ward stepwise regression with the p < 0.05 threshold stop-
ping rule. If variables correlated with r ≥ 0.5, only one of 
them was included in the multivariate model. Receiver 
operating characteristic curves and the area under the 
curve (AUC) were used to analyse the discriminatory 
power of CLT with respect to CVD. Two-sided p-val-
ues < 0.05 were considered statistically significant.
The study was powered to have a 80% chance of detect-
ing a 30% difference in cfDNA using a significance level 
of 0.05, based on the values of cfDNA in T2DM patients 
in the previous study [17]. To demonstrate such a dif-
ference or greater, 20 patients or more were required in 
each group.
All calculations were performed with  JMP®, Version 
14.0.0 SAS Institute Inc., Cary, NC.
Results
The final analysis included 113 T2DM patients, 59 
(52.2%) men and 54 (47.8%) women, aged between 39 and 
79  years (mean 63.7 ± 8.2  years). Sixty (53.1%) patients 
were treated with oral hypoglycaemic drugs, 32 (28.3%) 
with insulin and oral drug, 13 (11.5%) with insulin, and 
8 (7.1%) patients had only dietary therapy. HbA1c levels 
ranged from 5.1 to 12.1% (median 6.9%, 52 mmol/mol). 
Median time since T2DM diagnosis was 7.0 (3.0-15.0) 
years. Among 53 (46.9%) patients with CVD, there were 
21 (18.6%) with previous MI, 10 (8.9%) with PAD, and 5 
patients (4.4%) suffered from stroke or transient ischemic 
attack in the past. As expected, H3Cit correlated with 
cfDNA (r = 0.53, p < 0.001). The two markers positively 
associated with myeloperoxidase (r = 0.36, p < 0.001 and 
r = 0.26, p = 0.006) but not with NE.
Associations with patient characteristics
Gender, BMI, and smoking did not associate with 
NETosis markers. Patients with high H3Cit, defined 
as ≥ 7.36 ng/mL (upper quartile), did not differ from the 
remainder with regard to demographic data and comor-
bidities, except for MI being more prevalent among 
patients with high H3Cit (Table 1). This was also the case 
for patients with high cfDNA, defined as ≥ 2.84  µg/mL 
(upper quartile). Patients following MI had higher H3Cit 
(+108%; 8.57 [5.52–11.08] vs. 4.13 [2.97–6.39] ng/mL, 
p < 0.001, Fig. 1a) and higher cfDNA (+45%; 2.92 [1.57–
3.74] vs. 2.01 [1.53–2.67] µg/mL, p = 0.022, Fig. 1b) when 
compared with the remainder. Median time from the MI 
was 7.0 (2.2–12.0) years. There was an inverse correlation 
between cfDNA and time since MI (r = − 0.69, p = 0.001). 
Regarding microangiopathic complications, patients with 
and without albuminuria did not differ in terms of circu-
lating markers of NETosis (data not shown). 
Patients treated with metformin had longer time since 
T2DM diagnosis (8.0 [4.0–15.0] vs. 5.0 [0.4–9.5]  years, 
p = 0.020), increased H3Cit (4.70 [3.35–8.23] vs. 3.50 
[2.21–6.22] ng/mL, p = 0.010) and prolonged CLT 
(97.42 ± 19.26 vs. 87.59 ± 17.39 min, p = 0.020), irrespec-
tive of HbA1c and fasting glucose levels, which were 
comparable among those two groups of patients. Con-
versely, cfDNA was unaffected by metformin therapy. 
Treatment with aspirin or statin was not associated with 
lower H3Cit or cfDNA (data not shown).
Patients with high H3Cit did not differ in regard to rou-
tine laboratory test results compared with the remainder 
(Table  1). Higher HbA1c (+15.6%) and fasting glucose 
(+20.4%) were observed in patients with high cfDNA 
when compared with the rest of the study group (Table 1). 
Cell-free DNA was higher in patients with HbA1c in 
the third quartile when compared to those in the first 
quartile (+49.4%, p = 0.012, Fig.  2a). Concentrations of 
cfDNA were higher in patients with fasting glucose in 
the third and fourth quartiles compared with those in the 
first quartile (+43.2%, p < 0.001 and +51.1%, p = 0.006, 
respectively, Fig.  2b). cfDNA correlated with fasting 
glucose (r = 0.415, p < 0.001, Fig.  3a) and with HbA1c 
(r = 0.283, p = 0.003, Fig.  3b). HbA1c ≥ 8.0% was associ-
ated with approximately 2.5-fold greater odds of having 
high cfDNA (OR 2.55, 95% CI 1.04–6.29, p = 0.040).
Predictors of H3Cit and cfDNA
On multivariate logistic regression analysis adjusted 
for age and gender, predictors of high H3Cit in T2DM 
patients were: HbA1c ≥ 7.0% (OR 5.21, 95% CI 1.34–
24.83, p = 0.016) and IL-6 (OR 2.40, 95% CI 1.76–3.61, 
p < 0.001). Interleukin-6 was also found to be a predic-
tor of high cfDNA (OR 1.60, 95% CI 1.27–2.10, p < 0.001) 
along with glucose (OR 1.62, 95% CI 1.27–2.14, p < 0.001).
Associations with coagulation, fibrinolysis, 
and inflammatory markers
H3Cit correlated weakly with fibrinogen, plasminogen, 
PAI-1, and TAFI (all r < 0.25, all p < 0.05; Table 2). cfDNA 
showed similar weak correlations with PAI-1 and TAFI. 
Patients with high H3Cit trended to have slightly higher 
thrombomodulin (+7%, Table  2). Importantly, H3Cit 
and cfDNA inversely correlated with  Ks (r = − 0.431 and 
r = − 0.381, both p < 0.001, Fig.  3c, d), while there were 
strong positive associations of both H3Cit and cfDNA 
with CLT (r = 0.590 and r = 0.457, both p < 0.001, Fig. 3e, 
f, Table 2). cfDNA, but not H3Cit, correlated with peak 
thrombin (r = 0.391, all p < 0.001, Table  2), but not with 
other TG parameters. Myeloperoxidase correlated 
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Table 1 Comparison of patient characteristics in relation to citrullinated histone 3 (H3Cit) and cell-free deoxyribonucleic 
acid (cfDNA)
Variable Patients 
with H3Cit ≥ 7.36  
ng/mL (n = 28)
Patients 
without H3Cit < 7.36  
ng/mL (n = 84*)
p-value Patients 
with cfDNA ≥ 2.84 µg/
mL (n = 28)
Patients 
with cfDNA < 2.84 µg/
mL (n = 84*)
p-value
Demographic data
 Age, years 64.6 ± 7.1 63.5 ± 8.6 0.52 63.1 ± 7.4 64.0 ± 8.5 0.63
 Male gender, n (%) 11 (39.3) 47 (55.9) 0.12 13 (46.4) 45 (53.6) 0.51
 BMI, kg/m2 30.5 (27.4–37.8) 32.5 (29.6–36.8) 0.11 32.1 (29.5–37.7) 32.0 (29.1–36.2) 0.61
Type 2 diabetes data
 HbA1c, % 7.55 (6.23–8.58) 6.80 (6.00–8.20) 0.18 7.80 (6.73–8.90) 6.70 (6.00–8.00) 0.006
 HbA1c, mmol/mol 57.0 (43.0–69.4) 51.0 (42.0–66.1) 0.29 61.0 (50.0–70.5) 50.0 (41.0–64.0) 0.010
 Time since type 2 diabetes 
diagnosis, years
7.5 (5.0–17.5) 7.0 (2.3–12.8) 0.16 7.0 (5.0–18.5) 7.0 (2.5–12.0) 0.19
Comorbidities, n (%)
 Current or former smoking 14 (50.0) 48 (56.5) 0.66 13 (46.4) 49 (57.6) 0.38
 Arterial hypertension 27 (96.4) 77 (91.7) 0.68 27 (96.4) 77 (91.7) 0.68
 Cardiovascular disease 16 (57.1) 36 (42.9) 0.19 15 (53.6) 37 (44.1) 0.38
 Previous myocardial  
infarction
11 (39.3) 9 (10.7) < 0.001 10 (35.7) 11 (12.9) 0.004
 Family history of  
cardiovascular disease
9 (32.1) 21 (25.0) 0.46 4 (14.3) 26 (31.0) 0.63
 Heart failure 4 (14.3) 4 (4.8) 0.11 3 (10.7) 5 (6.0) 0.41
 GFR ≤ 60 mL/min/1.73 m2 4 (14.3) 12 (14.5) 1.0 6 (21.4) 10 (12.1) 0.22
 ACR ≥ 30 mg/g creatinine 6 (21.4) 15 (17.9) 0.74 3 (10.7) 18 (21.2) 0.18
Medication, n (%)
 Aspirin 18 (64.3) 55 (65.5) 0.91 19 (67.9) 54 (64.3) 0.73
 Clopidogrel 4 (14.3) 5 (5.9) 0.22 4 (14.3) 5 (5.9) 0.22
 β-blocker 20 (71.4) 61 (72.6) 0.90 21 (75.0) 60 (71.4) 0.71
 Statin 19 (67.9) 55 (65.5) 0.82 19 (67.9) 55 (65.5) 0.81
 ACEI 16 (57.1) 46 (54.8) 0.83 18 (64.3) 44 (52.3) 0.27
 Angiotensin receptor 
blocker
11 (39.3) 24 (28.6) 0.29 8 (28.6) 27 (32.1) 0.72
 Calcium antagonist 15 (53.6) 33 (39.3) 0.19 13 (46.4) 35 (41.7) 0.66
 Thiazide diuretics 10 (35.7) 26 (30.9) 0.64 9 (32.1) 27 (32.1) 1.0
 Indapamide 5 (17.9) 21 (25.0) 0.44 5 (17.9) 21 (25.0) 0.44
 Loop diuretics 7 (25.0) 14 (16.7) 0.33 7 (25.0) 14 (16.7) 0.33
Hypoglycemic treatment, n (%)
 No hypoglycemic drugs 0 (0) 8 (9.5) 0.20 1 (3.6) 7 (8.3) 0.68
 Oral drug 16 (57.1) 44 (52.4) 0.39 15 (53.5) 45 (53.6) 0.78
 Insulin 3 (10.8) 9 (10.7) 0.66 3 (10.8) 9 (10.7) 0.66
 Insulin and oral drug 9 (32.1) 23 (27.4) 0.63 9 (32.1) 23 (27.4) 0.64
Laboratory investigations
 White blood cells 
count, × 106/L 6.77 (5.72–8.87) 7.32 (6.45–8.49) 0.36 6.72 (5.78–8.17) 7.32 (6.45–8.54) 0.19
 Hemoglobin, g/dL 13.4 (12.5–14.2) 13.9 (13.0–14.7) 0.03 13.4 (12.5–14.0) 14.0 (130–14.8) 0.014
 Platelet count, × 109/L 227.5 (198–270) 230.0 (185–272) 0.94 2167 (191–251) 232 (186–278) 0.42
 Fasting glucose, mmol/L 7.40 (6.63–8.80) 7.14 (5.82–8.44) 0.28 8.07 (7.05–11.11) 6.70 (5.80–7.90) < 0.001
 GFR, mL/min/m2 86.5 (73.0–92.5) 82.0 (68.5–92.0) 0.42 80.5 (67.0–92.0) 84.5 (71.0–92.5) 0.17
 Alanine aminotransferase, 
U/L
24.0 (18.0–37.5) 26.5 (21.0–40.8) 0.30 27.5 (20.0–39.0) 26.0 (20.0–40.0) 0.58
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with CLT (r = 0.253, p = 0.007), but not with  Ks or TG. 
As expected, both H3Cit and cfDNA correlated with 
IL-6 and IL-8 (all p < 0.001), with the highest coefficient 
observed between H3Cit and IL-6 (r = 0.711, Table  2). 
Myeloperoxidase, but not NE, associated with IL-6 and 
IL-8 (r = 0.306 and r = 0.372, both p < 0.001).
Predictors of thrombin generation, clot density and lysis
In univariate linear regression analysis, cfDNA explained 
15.3% of the variation in peak thrombin generated in 
T2DM patients, while the corresponding value for 
H3Cit was negligible (about 1%). In multivariate regres-
sion analysis adjusted for age, gender, and fibrinogen, 
cfDNA was a predictor of peak thrombin generated 
(Table  3). In univariate regression analysis, H3Cit and 
cfDNA accounted for < 1% of the variation in AUC (data 
not shown), while for 18.6% and 9.7% of the variation in 
 Ks respectively. In a multivariate model adjusted for age, 
gender, and fibrinogen, H3Cit, but not cfDNA, was found 
to be an independent predictor of  Ks (Table 3).
In our patients, H3Cit explained 35.2%  and cfDNA 
accounted for 20.9% of the variation in CLT, while the 
corresponding values for PAI-1 and TAFI were 13.8% and 
3.6%, respectively. In multivariate linear regression analy-
sis adjusted for age, gender, and fibrinogen, both H3Cit 
and cfDNA were predictors of CLT, alongside with PAI-1 
and concomitant CVD (Table  3). Of note, time since 
diagnosis of T2DM ≥ 10  years contributed to CLT in a 
regression model incorporating H3Cit.
Table 1 (continued)
Variable Patients 
with H3Cit ≥ 7.36  
ng/mL (n = 28)
Patients 
without H3Cit < 7.36  
ng/mL (n = 84*)
p-value Patients 
with cfDNA ≥ 2.84 µg/
mL (n = 28)
Patients 
with cfDNA < 2.84 µg/
mL (n = 84*)
p-value
 Total cholesterol, mmol/L 3.94 (3.45–5.48) 4.26 (3.50–5.27) 0.79 4.09 (3.76–5.12) 4.23 (3.40–5.50) 0.85
 LDL-cholesterol, mmol/L 2.29 (1.75–3.81) 2.54 (1.17–3.43) 0.80 2.40 (1.76–3.41) 2.57 (1.80–3.57) 0.39
 HDL-cholesterol, mmol/L 1.35 (1.09–1.49) 1.14 (0.98–1.45) 0.11 1.22 (1.00–1.45) 1.15 (1.03–1.48) 0.76
 Triglycerides, mmol/L 1.49 (1.06–1.87) 1.54 (1.19–2.10) 0.29 1.74 (1.26–5.62) 1.48 (1.16–1.89) 0.12
 C-reactive protein, mg/L 2.90 (1.09–4.75) 2.33 (1.20–5.14) 0.94 3.43 (1.26–5.62) 2.33 (1.11–4.22) 0.26
Values are given as mean ± SD or median (interquartile range)
BMI, body mass index; HbA1c, glycated hemoglobin; GFR, glomerular filtration rate; ACR, albumin-to-creatinine ratio; ACEI, angiotensin-converting-enzyme inhibitor; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein
* Data on H3Cit and cfDNA levels were missing for one patient
Fig. 1 Citrullinated histone 3 (H3Cit, a) and cell-free deoxyribonucleic acid (cfDNA, b) in type 2 diabetes mellitus (T2DM) patients with previous 
myocardial infarction (MI, black dots) and the remainder (white dots). p-values were computed using the Mann–Whitney U test. Data on H3Cit and 
cfDNA levels were missing for one patient. Horizonal lines represent the median in each group
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Associations with CVD
When patients with T2DM and CVD were analysed sep-
arately, we observed longer CLT compared to subjects 
without CVD (102.50 [87.00–116.50] vs. 86.50 [77.50–
99.00] minutes, p < 0.001). Prolonged CLT ≥ 100 min was 
associated with approximately 4.7-fold higher risk of con-
comitant CVD (OR 4.67, 95% CI 2.03–10.76, p = 0.002). 
CLT ≥ 100  min could be identified with H3Cit value 
of ≥ 7.4 ng/mL (OR 11.00, 95% CI 3.89–31.14, p < 0.001, 
AUC 0.71) and with cfDNA value of ≥ 2.53  µg/mL (OR 
4.38, 95% CI 1.91–10.04, p < 0.001, AUC 0.67). T2DM 
patients with CVD did not differ from patients without 
CVD in regard to TG parameters and  Ks.
Discussion
Our study is the first to investigate factors which deter-
mine circulating markers of NETosis and cell death in the 
largest group of T2DM patients to date, along with their 
associations with a prothrombotic state and fibrinoly-
sis in this disease. The principal finding of this study is 
that elevated circulating markers of NETosis are associ-
ated with enhanced peak thrombin generation, decreased 
clot permeability, and impaired fibrinolysis in patients 
with T2DM. Our findings suggest that in T2DM patients, 
H3Cit and cfDNA could be regarded as two of the pre-
viously unknown contributors to the unfavourable clot 
phenotype, in addition to fibrinolysis inhibitors such as 
PAI-1 and TAFI [4]. Importantly, T2DM patients with 
prior MI are characterized by especially elevated mark-
ers of NETosis. We also found that glycaemic control, 
and inflammatory state reflected by IL-6, are related to 
NETosis in T2DM patients, indirectly modulating pro-
thrombotic alterations in blood. The present study yields 
new insights into the determinants of NETosis in T2DM 
and its impact on thrombotic tendency, which may have 
clinical implications.
Our study provided several factors linked with 
increased circulating levels of cfDNA and H3Cit. We 
have extended previous reports on a positive correla-
tion between HbA1c and nucleosomes or dsDNA [17] 
by showing that HbA1c exceeding 8.0% is associated 
with almost threefold higher odds of detecting high 
cfDNA in the blood of T2DM patients. Although DNA 
is a major component of NETs, it can be also released 
from cells other than neutrophils during the process of 
cell death. Therefore, cfDNA should be regarded as a 
less specific marker of NETosis when compared with 
H3Cit, result of enzyme peptidyl arginine-deiminase 4 
activity in the early phase of NETs formation [31, 32]. To 
the best of our knowledge, our study is the first to show 
that circulating H3Cit in T2DM patients is increased in 
patients with HbA1c above 7.0%, after adjusting for IL-6, 
a potent inducer of NETs as evidenced by Joshi et  al. 
[16]. In the present study, higher cfDNA concentrations 
were observed in patients with elevated fasting glycae-
mia, which is in line with documented in  vitro direct 
Fig. 2 Cell free DNA (cfDNA) in patients with glycated haemoglobin (HbA1c) categorised in 4 quartiles (a), and in patients with fasting glucose 
categorised in 4 quartiles (b). Groups were compared using the Kruskal–Wallis test, p-values were computed using the Steel–Dwass method. Data 
on cfDNA levels were missing for one patient. Horizonal lines represent the median in each group
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stimulating effects of hyperglycaemia on NETs release 
[17]. Higher circulating H3Cit concentrations in patients 
on metformin without differences in cfDNA are surpris-
ing given the data on its normalizing effect on NET lev-
els reported by Carestia et al. [19]. However, there were 
differences in the study design and patient characteris-
tics between that study and ours. Firstly, the mean age 
of patients studied by Carestia et  al. was 50  years, they 
had newly diagnosed T2DM, and none of them had 
thrombotic event during follow-up (thrombotic events 
in the past were not presented), whereas the mean age 
of the patients enrolled in our study was approximately 
64 years, their time since T2DM was 7 years (interquartile 
range 3–15 years), and 21 (18.6%) patients had previous 
MI, indicating higher cardiovascular risk in the current 
study. It might be hypothesized that higher H3Cit levels 
in metformin-treated patients reflect long-term T2DM 
associated with effects of aging, cardiovascular diseases 
and poor diabetic control. In our study, patients treated 
with metformin had longer time since T2DM diagno-
sis compared with the subjects not receiving this agent. 
Neutrophil-associated prothrombotic effects may sustain 
in diabetic patients with longer disease duration (the so-
called “prothrombotic memory”) as demonstrated in the 
Fig. 3 Correlations between fasting glucose and cell-free deoxyribonucleic acid (cfDNA, a), glycated haemoglobin (HbA1c) and cfDNA (b), 
citrullinated histone 3 (H3Cit) and clot lysis time (CLT, c), cfDNA and CLT (d), H3Cit and clot permeability  (Ks, e), and cfDNA and  Ks (f). Correlation 
coefficients were computed using Spearman’s rank correlation test. Data on H3Cit and cfDNA levels were missing for one patient
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study by Konieczynska et al. [28]. Those effects involved 
enhanced oxidative stress, endothelial injury, increased 
thrombin formation. The contribution of NETosis to the 
“prothrombotic memory” in long-standing T2DM should 
be further explored.
Unexpectedly, we observed a significant impact of 
NETosis on efficiency of fibrinolysis assessed using 
a global lysis test in T2DM patients. In our study, an 
elevation of H3Cit by 1  ng/mL was associated with 
an increase in CLT by 2.7  min, while an elevation of 
cfDNA by 1 µg/mL was associated with increase of CLT 
by 8.3  min. This might suggest that despite inconsist-
ent effects of histones and cfDNA on fibrin clot lysis in 
purified systems [14, 15], in T2DM with concomitant 
inflammatory state, H3Cit and cfDNA might contrib-
ute to hypofibrinolysis. In an in vitro study, addition of 
histones to fibrin influenced clot structure, resulting in 
denser fibrin clot and thicker fibrin fibres [14]. T2DM is 
a typical disease in which the prothrombotic fibrin clot 
phenotype has been observed [33]. In ex vivo studies, a 
key measure of plasma clot structure is its permeability, 
reflected by the Darcy constant  (Ks) [33]. Our original 
observation is that H3Cit is an independent predictor 
of clot permeability in T2DM. In multivariate analysis, 
cfDNA did not contribute to  Ks, supporting in  vitro 
observations showing that the effects of DNA on clot 
structure are minor [14].
Of note, previous MI was found in our study to be 
a key clinical factor associated with elevated H3Cit, 
cfDNA, and CLT among T2DM patients. Recent data 
has strongly supported the role of NETs in atheroscle-
rosis and atherothrombosis [34], including mediat-
ing MI in the mouse model [35]. MI is a manifestation 
of coronary atherosclerosis, which has been reported 
to be associated with elevated plasma biomarkers of 
NETs such as double-stranded DNA, nucleosomes, and 
Table 2 Comparison of  coagulation and  fibrinolysis proteins and  clot phenotype parameters in  patients in  relation 
to citrullinated histone 3 (H3Cit) and cell-free deoxyribonucleic acid (cfDNA)
Values are given as mean ± SD or median (interquartile range)
PAI-1, plasminogen activator inhibitor 1; TAFI, thrombin activatable fibrinolysis inhibitor; ETP, endogenous thrombin potential;  Ks, Darcy’s constant (permeability 
coefficient)
* Data on H3Cit and cfDNA levels were missing for one patient
Variable Patients 
with H3Cit ≥ 7.36 ng/
mL
(n = 28)
Patients 
without H3Cit < 7.36 ng/
mL
(n = 84*)
p-value Patients 
with cfDNA ≥ 2.84 µg/
mL
(n = 28)
Patients 
with cfDNA < 2.84 µg/
mL
(n = 84*)
p-value
Coagulation and fibrinolysis components
 Fibrinogen, g/L 3.54 (3.20–4.02) 3.45 (3.09–3.85) 0.17 3.56 (3.17–3.87) 3.44 (3.10–3.9) 0.44
 α2-antiplasmin,  % 106.0 (102.0–112.0) 103.0 (96.0–110.0) 0.07 104.5 (96.0–111.5) 104.0 (98.0–110.0) 0.88
 Plasminogen,  % 110.0 (101.5–118.5) 108.0 (99.0–120.0) 0.55 109.5 (97.5–127.5) 109.0 (100.0–118.8) 0.75
 PAI-1, ng/mL 36.4 (32.0–45.4) 35.0 (30.6–40.9) 0.19 37.6 (33.0–44.8) 35.0 (30.8–40.9) 0.13
 TAFI,  % 104.0 (96.5–119.3) 101.5 (90.0–114.0) 0.06 109.0 (93.5–120.5) 102.0 (90.0–113.8) 0.07
Endothelial injury marker
 Thrombomodulin, 
ng/mL
3.02 (2.45–3.80) 2.80 (2.35–3.11) 0.056 2.95 (2.47–3.73) 2.74 (2.33–3.19) 0.13
Interleukins
 Interleukin 6, pg/mL 7.19 (5.17–8.78) 3.02 (2.19–4.63) < 0.001 6.14 (3.25–8.46) 3.52 (2.22–5.19) < 0.001
 Interleukin 8, pg/mL 8.26 (6.08–9.37) 4.28 (3.29–6.27) < 0.001 7.72 (4.83–9.22) 4.73 (3.61–6.79) < 0.001
Thrombin generation
 Lag phase, s 1053 (763–1343) 1004 (777–1350) 0.82 897 (762–1182) 1,050 (789–1383) 0.13
 Peak thrombin, nmol 115.7 (90.0–166.6) 116.8 (87.7–153.5) 0.45 142.3 (100.0–188.0) 112.5 (86.6–147.2) 0.012
 Time-to-peak, s 1369 (1067–2035) 1395 (1128–1889) 0.94 1184 (1019–1559) 1417 (1149–1892) 0.08
 ETP, nM × s 104,732 (92,039–122,405) 103,810 (83,751–126,823) 0.93 111,864 (94,181–134,420) 103,810 (81,390–121,805) 0.26
Platelet markers
 P-selectin, ng/mL 62.9 (46.1–88.1) 72.4 (52.4–91.7) 0.45 70.7 (47.0–88.4) 68.1 (51.43–91.7) 0.63
 Platelet factor 4, ng/
mL
80.5 (64.8–89.6) 82.0 (70.7–90.8) 0.40 80.5 (72.2–88.7) 82.6 (68.9–91.3) 0.45
Clot permeability
 Ks, × 10−9  cm2 5.90 (5.15–6.40) 6.65 (6.20–7.10) < 0.001 6.20 (5.58–6.88) 6.50 (6.00–7.00) 0.022
Clot lysis time, min 114.0 (99.3–126.8) 87.0 (78.3–100.0) < 0.001 103.5 (90.0–125.0) 89.0 (79.0–103.0) 0.001
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myeloperoxidase–DNA complexes [13]. Increased extra-
cellular DNA has been observed in T2DM patients with 
CVD when compared to those without CVD [17]. Con-
sistent with the theory of early NETS as an early bio-
marker of tissue injury in myocardial infarction [36], we 
observed an inverse correlation between cfDNA and time 
since MI. Boristoff et al. demonstrated that myeloperoxi-
dase–DNA complexes predicted the occurrence of major 
adverse cardiac events (MACE), however, patients with 
T2DM accounted for a small proportion of patients with 
MACE [13]. Our study extends these previous observa-
tions by suggesting that biomarkers of NETosis could be 
potential candidates for further evaluation in the pre-
diction of MACE within the subset of diabetic patients. 
Since we found that H3Cit ≥ 7.4  ng/mL was associated 
with 11-fold increased odds of prolonged CLT, it might 
be speculated that H3Cit measured in blood could be 
regarded as an additional marker of increased cardiovas-
cular risk in T2DM. It cannot be excluded that H3Cit, 
via prolonged CLT, also contributes to an increased risk 
of venous thromboembolism in T2DM, although data 
regarding the impact of T2DM on venous thrombosis are 
inconsistent [37].
It has been previously shown that in patients with CAD, 
markers of cell death and NETs formation were positively 
associated with TG [13]. TG has been suggested to con-
tribute to the hypercoagulable state in T2DM to a smaller 
extent than impairment of fibrinolysis [38, 39]. We found 
that cfDNA may predict peak thrombin measured using 
the CAT assay, with no impact on endogenous thrombin 
potential. Extracellular histones have been demonstrated 
to promote TG through platelet-dependent mechanisms 
[12]. It is possible that the use of platelet-poor-plasma in 
our study explains the weak effect of NETosis on throm-
bin formation in this assay. It remains to be established 
whether platelet-rich plasma obtained from T2DM 
patients may result in more potent associations between 
NETosis markers and TG potential. Although patients 
with high H3Cit trended to have slightly higher throm-
bomodulin, this concentration was likely insufficient to 
mediate enhancement of plasma TG as observed in puri-
fied systems [40].
The limitations of our study include those which are 
inherent to observational studies. Although the size of 
our study population was rather small, it was represent-
ative of real-life T2DM patients from Poland with rela-
tively good glycaemic control. Moreover, the study was 
sufficiently powered to show the difference in cfDNA 
between patients with and without MI based on a previ-
ous study in T2DM patients [17]. Since we assessed gly-
caemia once, we did not assess potential links of NETosis 
with varying plasma glucose in T2DM, especially with 
episodes of hypoglycaemia, which is known to contrib-
ute to a worse prognosis, resistance to lysis, and com-
pact fibrin clot formation [41]. All reported associations 
cannot be necessarily considered as cause-and-effect 
Table 3 Univariate and  multivariate models for  predictors of  peak thrombin, clot permeability  (Ks) and  clot lysis time 
(CLT)
BMI, body-mass index; PAI-1, plasminogen-activator inhibitor type 1; T2DM, type 2 diabetes mellitus; CVD, cardiovascular disease
Data are presented as regression coefficients derived from the univariate and multivariate regression models. Due to the strong correlation between citrullinated 
histone 3 (H3Cit) and cell-free deoxyribonucleic acid (cfDNA), two separate multivariate models for CLT were provided
* Adjusted for age, gender and fibrinogen
Predictors U β (95% CI) p-value M β (95% CI)* p-value
Peak thrombin
 cfDNA 40.83 (22.65 to 59.02) < 0.001 17.10 (7.24 to 26.95) < 0.001
 Metformin 12.68 (− 34.07 to 8.71) 0.24 − 14.5 (− 25.20 to − 3.85) 0.008
 BMI 1.23 (− 2.13 to 4.59) 0.47 1.86 (0.24 to 3.48) 0.025
Ks
 H3Cit − 0.10 (− 0.14 to − 0.06) < 0.001 − 0.08 (− 0.11 to − 0.04) < 0.001
CLT
 H3Cit 3.06 (2.28 to 3.85) < 0.001 2.70 (1.93 to 3.46) < 0.001
 PAI-1 1.00 (0.52 to 1.46) < 0.001 0.58 (0.17 to 0.99) 0.006
 CVD 7.09 (3.73 to 10.46) < 0.001 3.91 (1.05 to 6.76) 0.008
 Time since T2DM diagno-
sis ≥ 10 years
4.26 (0.64 to 7.88) 0.022 3.15 (0.30 to 6.01) 0.031
CLT
 cfDNA 9.38 (5.93 to 12.83) < 0.001 8.26 (5.04 to 11.48) < 0.001
 PAI-1 1.00 (0.52 to 1.46) < 0.001 0.80 (0.37 to 1.23) < 0.001
 CVD 7.09 (3.73 to 10.46) < 0.001 5.46 (2.49 to 8.43) < 0.001
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relationships, however, they are largely in line with 
in vitro data published in the literature [14, 15]. We did 
not assess the extent of oxidation as a potential modi-
fier of NETosis and fibrin properties in this study [42]. A 
large prospective study with a long-term follow-up would 
be required to assess whether NETosis and its association 
with the prothrombotic blood alterations reported here, 
is related to adverse clinical events, including cardiovas-
cular death, in T2DM.
Conclusions
In T2DM, NETosis markers in circulating plasma, such 
as H3Cit and cfDNA, are related to glycemia control, 
systemic low-grade inflammation markers and previous 
MI. Enhanced NETosis detectable in circulating blood is 
associated with a prothrombotic state, especially hypofi-
brinolysis in T2DM patients. The present study shows 
that NETosis might contribute to thrombotic and cardio-
vascular risk in that disease. A role of NETs generation 
in the natural course of diabetes and its complications 
deserves further investigations.
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